What is Travere Therapeutics, Inc.'s revenue?

Travere Therapeutics, Inc. (TVTX) reported revenue of $127.2M in Q1 2026.

How has Travere Therapeutics, Inc.'s revenue changed year-over-year?

Travere Therapeutics, Inc.'s revenue increased by 55.6% year-over-year, from $81.73M to $127.2M.

What is the long-term trend for Travere Therapeutics, Inc.'s revenue?

Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s revenue has grown at a 64.9% compound annual growth rate (CAGR), from $109.46M to $490.73M.

Travere Therapeutics, Inc. TVTX Revenue

Revenue at other companies

HTF

Heartflow, Inc. Common StockHTFL

$52.59M+41.3%

Cal-Maine FoodsCALM

$666.95M-53.0%

DJT

Trump Media & Technology GroupDJT

$871.2K+6.1%

ADMA BiologicsADMA

$114.49M-0.3%

Minerals TechnologiesMTX

$546.9M+11.2%

PhotronicsPLAB

$209.94M-0.5%

Other financials

Income statement

See full

Revenue$127.2M+55.6%

Gross profit$125.2M+62.5%

Operating income-$36.9M+13.5%

Net income-$37.1M+10.0%

EPS (diluted)-$0.40+14.9%

Balance sheet

See full

Cash & equivalents$78.4M+26.6%

Total debt$15.6M-82.6%

Total equity$98.7M+201%

Total assets$555.2M+1.2%

Cash flow

See full

Operating cash flow-$40.4M+4.3%

CapEx$140.0K—

Free cash flow-$42.5M+28.1%

Valuation

See full

Market cap$5.2B+72.3%

Profitability

See full

Gross margin98.6%+2.6pp

Operating margin-10.6%-5.0pp

Net margin-20.3%-9.5pp

FCF margin-133.9%-34.4pp

Returns & leverage

See full

Return on equity-706%-1,302pp

Debt / equity0.2×-2.6×

Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s revenue?: Travere Therapeutics, Inc. (TVTX) reported revenue of $127.2M in Q1 2026.
How has Travere Therapeutics, Inc.'s revenue changed year-over-year?: Travere Therapeutics, Inc.'s revenue increased by 55.6% year-over-year, from $81.73M to $127.2M.
What is the long-term trend for Travere Therapeutics, Inc.'s revenue?: Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s revenue has grown at a 64.9% compound annual growth rate (CAGR), from $109.46M to $490.73M.